Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 14/20 | 0.40 |
| ▸ | HTR2B | P41595 | 13/20 | 0.40 |
| ▸ | HTR2A | P28223 | 12/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29841752 | 0.81 | HTR2C (0.47) | HTR2CHTR2BHTR2ACHRNB2CHRNA4 | |
| SCHEMBL31244702 | 0.80 | HTR2C (0.40) | HTR2CHTR2BHTR2A | |
| SCHEMBL31244748 | 0.80 | HTR2C (0.40) | HTR2CHTR2BHTR2A | |
| SCHEMBL31244762 | 0.80 | HTR2C (0.40) | HTR2CHTR2BHTR2A | |
| SCHEMBL31244797 | 0.78 | HTR2A (0.41) | HTR2CHTR2BHTR2ACHRNB2CHRNA4 | |
| SCHEMBL24639831 | 0.77 | DRD2 (0.36) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL31244608 | 0.77 | HTR3A (0.39) | HTR2CHTR2BHTR2ACHRNB2CHRNA4 | |
| SCHEMBL31244622 | 0.76 | HTR2C (0.32) | HTR2CHTR2BHTR2ACHRNB2CHRNA4 | |
| SCHEMBL31244813 | 0.74 | HTR2C (0.51) | HTR2CHTR2BHTR2A | |
| SCHEMBL31244660 | 0.73 | HTR2C (0.62) | HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336629-A1 | Tricyclic Derivatives Useful As PARP7 Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-10-10 | — | — | US | claimed |
| US-20240336629-A1 | Tricyclic Derivatives Useful As PARP7 Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336629-A1 | Tricyclic Derivatives Useful As PARP7 Inhibitors | PARP1, PARP2, PARP11 | HTR2C 1125/4885HTR2B 726/4885HTR2A 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.